X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (469) 469
Publication (36) 36
Book / eBook (10) 10
Book Chapter (8) 8
Patent (4) 4
Dissertation (1) 1
Web Resource (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (169) 169
humans (164) 164
oncology (140) 140
male (86) 86
middle aged (83) 83
female (77) 77
lung neoplasms - drug therapy (76) 76
aged (72) 72
carcinoma, non-small-cell lung - drug therapy (72) 72
adult (63) 63
cancer (62) 62
chemotherapy (61) 61
respiratory system (61) 61
lung neoplasms - pathology (59) 59
lung neoplasms - genetics (57) 57
carcinoma, non-small-cell lung - genetics (49) 49
carcinoma, non-small-cell lung - pathology (48) 48
lung cancer (48) 48
lung cancer, non-small cell (40) 40
aged, 80 and over (39) 39
mutation (37) 37
prognosis (37) 37
antineoplastic agents - therapeutic use (36) 36
open-label (33) 33
neoplasm staging (32) 32
survival (32) 32
care and treatment (30) 30
metastasis (30) 30
treatment outcome (30) 30
antineoplastic combined chemotherapy protocols - therapeutic use (29) 29
nsclc (26) 26
immunotherapy (25) 25
non-small cell lung cancer (25) 25
patients (25) 25
lung neoplasms - mortality (24) 24
protein kinase inhibitors - therapeutic use (23) 23
tumors (23) 23
carcinoma, non-small-cell lung - mortality (22) 22
research (22) 22
nivolumab (20) 20
survival rate (19) 19
adenocarcinoma (18) 18
crizotinib (18) 18
hematology, oncology and palliative medicine (18) 18
retrospective studies (18) 18
docetaxel (17) 17
adenocarcinoma - drug therapy (16) 16
analysis (16) 16
cell lung-cancer (16) 16
life sciences (16) 16
receptor protein-tyrosine kinases - genetics (16) 16
safety (16) 16
disease-free survival (15) 15
egfr (15) 15
genetic aspects (15) 15
therapy (15) 15
expression (14) 14
follow-up studies (14) 14
medical research (14) 14
molecular targeted therapy (14) 14
non-small cell lung carcinoma (14) 14
pyrazoles - therapeutic use (14) 14
pyridines - therapeutic use (14) 14
animals (13) 13
bevacizumab (13) 13
biomarkers, tumor - genetics (13) 13
cancer therapies (13) 13
gene (13) 13
lung cancer, small cell (13) 13
lung neoplasms - metabolism (13) 13
medicine & public health (13) 13
non-small-cell lung cancer (13) 13
thymoma (13) 13
acquired-resistance (12) 12
biomarkers (12) 12
carboplatin (12) 12
carcinoma (12) 12
carcinoma, non-small-cell lung - metabolism (12) 12
cisplatin (12) 12
gefitinib (12) 12
melanoma (12) 12
prospective studies (12) 12
receptor, epidermal growth factor - genetics (12) 12
1st-line treatment (11) 11
brain metastases (11) 11
cell biology (11) 11
clinical trials (11) 11
lung neoplasms - enzymology (11) 11
lung neoplasms - therapy (11) 11
surgery (11) 11
young adult (11) 11
antineoplastic combined chemotherapy protocols - adverse effects (10) 10
breast-cancer (10) 10
carcinoma, non-small-cell lung - therapy (10) 10
cell line, tumor (10) 10
cisplatin - administration & dosage (10) 10
gene expression profiling (10) 10
gene rearrangement (10) 10
lung neoplasms - diagnosis (10) 10
medicine (10) 10
more...
Library Location Library Location
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Numerische Mathematik, ISSN 0029-599X, 6/2018, Volume 139, Issue 2, pp. 281 - 314
Journal Article
Journal of Computational Physics, ISSN 0021-9991, 09/2017, Volume 345, pp. 484 - 509
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 06/2013, Volume 368, Issue 25, pp. 2385 - 2394
In a prospective, randomized, phase 3 trial of crizotinib as second-line therapy in patients who had disease progression while receiving a platinum-based... 
REARRANGEMENT | MEDICINE, GENERAL & INTERNAL | GEFITINIB | ONCOLOGY | EML4-ALK FUSION GENE | CLINICAL-TRIALS | PHASE-III | LYMPHOMA | OPEN-LABEL | DOCETAXEL | EGFR | Glutamates - therapeutic use | Lung Neoplasms - drug therapy | Pyrazoles - therapeutic use | Glutamates - adverse effects | Guanine - analogs & derivatives | Lung Neoplasms - mortality | Humans | Middle Aged | Male | Antineoplastic Agents - therapeutic use | Protein Kinase Inhibitors - adverse effects | Young Adult | Taxoids - therapeutic use | Pyridines - adverse effects | Antineoplastic Agents - adverse effects | Aged, 80 and over | Adult | Female | Guanine - adverse effects | Guanine - therapeutic use | Taxoids - adverse effects | Pyrazoles - adverse effects | Pyridines - therapeutic use | Kaplan-Meier Estimate | Carcinoma, Non-Small-Cell Lung - mortality | Pemetrexed | Disease-Free Survival | Protein Kinase Inhibitors - therapeutic use | Quality of Life | Aged | Carcinoma, Non-Small-Cell Lung - drug therapy | Tyrosine | Intravenous administration | Biomedical research | Lung cancer | Liver | Fatigue | Chromosome rearrangements | Cancer therapies | Patients | Lymphoma | Metastases | Ovarian cancer | Quality of life | Confidence intervals | Chemotherapy | Dyspnea | Alopecia | Platinum | Lymphomas | Respiration | Pharmaceutical industry | Protein-tyrosine kinase
Journal Article
The Lancet Oncology, ISSN 1470-2045, 12/2017, Volume 18, Issue 12, pp. 1590 - 1599
Journal Article
Nature, ISSN 0028-0836, 06/2018, Volume 558, Issue 7710, pp. 1 - 2
Journal Article
by Peifer, Martin and Fernández-Cuesta, Lynnette and Sos, Martin L and George, Julie and Seidel, Danila and Kasper, Lawryn H and Plenker, Dennis and Leenders, Frauke and Sun, Ruping and Zander, Thomas and Menon, Roopika and Koker, Mirjam and Dahmen, Ilona and Müller, Christian and Di Cerbo, Vincenzo and Schildhaus, Hans-Ulrich and Altmüller, Janine and Baessmann, Ingelore and Becker, Christian and De Wilde, Bram and Vandesompele, Jo and Böhm, Diana and Ansén, Sascha and Gabler, Franziska and Wilkening, Ines and Heynck, Stefanie and Heuckmann, Johannes M and Lu, Xin and Carter, Scott L and Cibulskis, Kristian and Banerji, Shantanu and Getz, Gad and Park, Kwon-Sik and Rauh, Daniel and Grütter, Christian and Fischer, Matthias and Pasqualucci, Laura and Wright, Gavin and Wainer, Zoe and Russell, Prudence and Petersen, Iver and Chen, Yuan and Stoelben, Erich and Ludwig, Corinna and Schnabel, Philipp and Hoffmann, Hans and Muley, Thomas and Brockmann, Michael and Engel-Riedel, Walburga and Muscarella, Lucia A and Fazio, Vito M and Groen, Harry and Timens, Wim and Sietsma, Hannie and Thunnissen, Erik and Smit, Egber and Heideman, Daniëlle A. M and Snijders, Peter J. F and Cappuzzo, Federico and Ligorio, Claudia and Damiani, Stefania and Field, John and Solberg, Steinar and Brustugun, Odd Terje and Lund-Iversen, Marius and Sänger, Jörg and Clement, Joachim H and Soltermann, Alex and Moch, Holger and Weder, Walter and Solomon, Benjamin and Soria, Jean-Charles and Validire, Pierre and Besse, Benjamin and Brambilla, Elisabeth and Brambilla, Christian and Lantuejoul, Sylvie and Lorimier, Philippe and Schneider, Peter M and Hallek, Michael and Pao, William and Meyerson, Matthew and Sage, Julien and Shendure, Jay and Schneider, Robert and Büttner, Reinhard and Wolf, Jürgen and Nürnberg, Peter and Perner, Sven and Heukamp, Lukas C and Brindle, Paul K and Haas, Stefan and Thomas, Roman K
Nature Genetics, ISSN 1061-4036, 10/2012, Volume 44, Issue 10, pp. 1104 - 1110
Journal Article
Nature, ISSN 0028-0836, 06/2018, Volume 558, Issue 7710, pp. 376 - 377
Activating immune cells to destroy tumours is an effective strategy for treating an advanced lung cancer -- but only for some people. Evidence that this... 
Care and treatment | Research | Lung cancer, Non-small cell | Immunotherapy | Oncology, Experimental | Cancer
Journal Article
Lancet, The, ISSN 0140-6736, 2016, Volume 387, Issue 10026, pp. 1415 - 1426
Journal Article
The Lancet Oncology, ISSN 1470-2045, 12/2018, Volume 19, Issue 12, pp. 1654 - 1667
Lorlatinib is a potent, brain-penetrant, third-generation inhibitor of ALK and ROS1 tyrosine kinases with broad coverage of mutations. In a phase 1 study,... 
MULTICENTER | EFFICACY | ONCOLOGY | CERITINIB | CRIZOTINIB | OPEN-LABEL | INHIBITOR | ROS1 | CHEMOTHERAPY | Care and treatment | Research | Lung cancer, Non-small cell | Analysis | Oncology, Experimental | Cancer
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2016, Volume 17, Issue 7, pp. 984 - 993
Summary Background BRAF mutations act as an oncogenic driver via the mitogen-activated protein kinase (MAPK) pathway in non-small cell lung cancer (NSCLC).... 
Hematology, Oncology and Palliative Medicine
Journal Article
Nature, ISSN 0028-0836, 06/2018, Volume 558, Issue 7710, pp. 376 - 377
[...]the optimal duration of nivolumab treatment remains to be determined, because delayed responses to ICTs can occur7. [...]some of the tumours that had high... 
Medical research | Immunoglobulins | Disease | Lung cancer | Genomes | Metastasis | Cancer therapies | Chemotherapy | Researchers | Immunotherapy | Surgery | Mutation | Cancer | Immune system | Tumors | Apoptosis
Journal Article